Medpace Holdings, Inc. is a scientifically-driven, global, full-service clinical contract research organization which provides Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace Holdings, Inc. is headquartered in Cincinnati, Ohio.
| Revenue (Most Recent Fiscal Year) | $2.53B |
| Net Income (Most Recent Fiscal Year) | $451.12M |
| PE Ratio (Current Year Earnings Estimate) | 34.19 |
| PE Ratio (Trailing 12 Months) | 35.25 |
| PEG Ratio (Long Term Growth Estimate) | 2.68 |
| Price to Sales Ratio (Trailing 12 Months) | 6.03 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 38.69 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 35.35 |
| Pre-Tax Margin (Trailing 12 Months) | 21.53% |
| Net Margin (Trailing 12 Months) | 17.67% |
| Return on Equity (Trailing 12 Months) | 110.15% |
| Return on Assets (Trailing 12 Months) | 24.84% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.73 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.73 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $16.30 |
| Earnings per Share (Most Recent Fiscal Quarter) | $4.25 |
| Earnings per Share (Most Recent Fiscal Year) | $15.28 |
| Diluted Earnings per Share (Trailing 12 Months) | $17.06 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Common Shares Outstanding | 27.91M |
| Free Float | 22.19M |
| Market Capitalization | $16.79B |
| Average Volume (Last 20 Days) | 0.35M |
| Beta (Past 60 Months) | 1.15 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 20.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 77.98% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |